ArticleInternational journal of molecular sciences2011
Proteomic analysis identified DJ-1 as a cisplatin resistant marker in non-small cell lung cancer.
Article in International journal of molecular sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 67 citations in OpenAlex.
- Potentially functional variants of PARK7 and DDR2 in ferroptosis-related genes predict survival of non-small cell lung cancer patients.International journal of cancer · 2025Article
- TrkB inhibition of DJ-1 degradation promotes the growth and maintenance of cancer stem cell characteristics in hepatocellular carcinoma.Cellular and molecular life sciences : CMLS · 2023Article
- Localized chemotherapy approaches and advanced drug delivery strategies: a step forward in the treatment of peritoneal carcinomatosis from ovarian cancer.Frontiers in oncology · 2023Review
- Chemical Toolkit for PARK7: Potent, Selective, and High-Throughput.Journal of medicinal chemistry · 2022Article
- TrkC-mediated inhibition of DJ-1 degradation is essential for direct regulation of pathogenesis of hepatocellular carcinoma.Cell death & disease · 2022Article
- Review
- DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.Oxidative medicine and cellular longevity · 2022Article
- DJ-1 promotes osteosarcoma progression through activating CDK4/RB/E2F1 signaling pathway.Frontiers in oncology · 2022Article
- Advances in the application of proteomics in lung cancer.Frontiers in oncology · 2022Review
- Bis-isatin derivatives: design, synthesis, and biological activity evaluation as potent dimeric DJ-1 inhibitors.Acta pharmacologica Sinica · 2021Article
- Protective role of DJ-1 in endotoxin-induced acute kidney injury.American journal of physiology. Renal physiology · 2020Article
- Novel Insights into PARK7 (DJ-1), a Potential Anti-Cancer Therapeutic Target, and Implications for Cancer Progression.Journal of clinical medicine · 2020Review
- An Integrated Meta-Analysis of Secretome and Proteome Identify Potential Biomarkers of Pancreatic Ductal Adenocarcinoma.Cancers · 2020Article
- DJ-1 suppresses ferroptosis through preserving the activity of S-adenosyl homocysteine hydrolase.Nature communications · 2020Article
- DJ-1 Alters Epirubicin-induced Apoptosis via Modulating Epirubicinactivated Autophagy in Human Gastric Cancer Cells.Current medical science · 2018Article
- Discovery and Optimization of Inhibitors of the Parkinson's Disease Associated Protein DJ-1.ACS chemical biology · 2018Article
- Intraperitoneal nanotherapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin.Nanomedicine : nanotechnology, biology, and medicine · 2018Article
- Key Players of Cisplatin Resistance: Towards a Systems Pharmacology Approach.International journal of molecular sciences · 2018Article
- Identification of DJ-1 as a contributor to multidrug resistance in human small-cell lung cancer using proteomic analysis.International journal of experimental pathology · 2017Article
- Quantum-dot-based suspension microarray for multiplex detection of lung cancer markers: preclinical validation and comparison with the Luminex xMAPScientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of study is to identify cisplatin-resistance associated biomarkers for non-small cell lung cancers (NSCLC). We use two-dimensional electrophoresis (2-DE) combined with MALDI-TOF mass spectrometry to compare the proteome between lung cancer cell line A549 and its cisplatin-resistant subline A549/DDP. Nine cisplatin resistance-related proteins were identified, and DJ-1, one of the differently expressed proteins, was selected for further validation and evaluation. Immunohistochemical results demonstrated that high expression level of DJ-1 was associated with cisplatin resistance and a predictor for poor prognosis in 67 locally advanced NSCLC patients. Furthermore, in vitro results showed that silencing DJ-1 increased the proliferation inhibitory effect of cisplatin to A549/DDP cells. In conclusion, DJ-1 might play an important role in the resistibility to cisplatin, and it could also act as a novel candidate biomarker for predicting the response of NSCLC patients to cisplatin-based chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.